Aspirin for the primary prevention of cardiovascular events

Graeme J Hankey and John W Eikelboom
Med J Aust 2002; 177 (7): . || doi: 10.5694/j.1326-5377.2002.tb04833.x
Published online: 7 October 2002

Benefits depend on the patient’s absolute cardiovascular and bleeding risks

The benefit of aspirin for patients with previous symptomatic atherothrombosis of the heart, brain and limb in the secondary prevention of recurrent serious vascular events is well established. However, the role of aspirin in the primary prevention of cardiovascular disease among people who have no symptoms of vascular disease is controversial.1 A recent summary of the evidence has prompted recommendations from the third US Preventive Services Task Force2,3 and the American Heart Association.4

  • Graeme J Hankey1
  • John W Eikelboom2

  • Royal Perth Hospital, Perth, WA.



remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.